Zobrazeno 51 - 60
of 1 548
pro vyhledávání: ''
Publikováno v:
Clinical Cancer Research. 25:4141-4154
Purpose: Hepatocellular carcinoma (HCC), one of the most common and deadliest malignancies worldwide, has a poor prognosis, owing to its high potential for vascular invasion and metastasis and the lack of biomarkers for early diagnosis. Thus, it must
Autor:
Alena Cristina Jaime-Ramirez, Yeshavanth Kumar Banasavadi-Siddegowda, Haroon Quadri, Tejaswini Nallanagulagari, Balveen Kaur, Mitra Nair, Tae Jin Lee, Manish K. Aghi, Ji Young Yoo, W. Shawn Carbonell, Joseph N. Liu, Kurt H. Bockhorst, Jeffrey Yunhua Guo, Jianying Zhang
Publikováno v:
Mol Cancer Ther
Integrin β1 receptor, expressed on the surface of tumor cells and macrophages in the tumor microenvironment (TME), has been implicated in both tumor progression and resistance to multiple modalities of therapy. OS2966 is the first clinical-ready hum
Autor:
Dana M. van Bemmel, Dorothy K. Hatsukami, Connie S. Sosnoff, Cindy M. Chang, Brian L. Rostron, Arseima Y. Del Valle-Pinero, Yuesong Wang, Maciej L. Goniewicz, Heather L. Kimmel, Bridget K. Ambrose, Kevin P. Conway, Joanne T. Chang, Benjamin C. Blount, Catherine G. Corey, Stephen Arnstein, Andrew Hyland, Kathryn C Edwards, Kristie Taylor, Lanqing Wang, Maocheng Yang, Mark J. Travers, Nicolette Borek
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: Given the diverse cigar market and limited data on biomarker patterns by cigar type, we compared biomarkers of nicotine and tobacco toxicants among cigar smokers and other groups. Methods: Using Wave 1 urinary biomarker data from 5,604 ad
Autor:
Michael B. Sporn, Di Zhang, Samir J. Ibrahim, Karen T. Liby, Ana S. Leal, Pamela A. Marshall, Carl E. Wagner, Pritika H. Shahani, San Raban, Peter W. Jurutka, Sarah Carapellucci, Jaskaran S. Bhogal
Publikováno v:
Cancer Prevention Research. 12:211-224
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the s
Autor:
I. Vanden Bempt, Ines Nevelsteen, Guiseppe Floris, J Goyens, H. Wildiers, K Punie, E Van Nieuwenhuysen, Patrick Neven, A Smeets, Ignace Vergote, S Vander Borght, Sileny Han
Publikováno v:
Cancer Research. 79:P3-08
Background: Clinical next-generation sequencing (NGS) has opened new perspectives on genome-driven therapy for metastatic breast cancer (MBC) through the identification of recurrent driver mutations. However, therapeutic relevance of the detection of
Publikováno v:
Cancer Research. 79:P6-20
Background: Estrogen receptor positive (ER+) breast cancers make up approximately 75% of all breast cancers diagnosed and ER, a protein encoded by the ESR1 gene, plays a major role in the initiation, growth and survival of these cancers. Current targ
Autor:
Isabelle Bedrosian, K. K. Hunt, CM Trinidad, Constance Albarracin, Anjana Bhardwaj, Harjeet Singh
Publikováno v:
Cancer Research. 79:P6-12
Background: Prevention of triple negative breast cancer (TNBC) is hampered by lack of knowledge about the drivers of tumorigenesis. Methods: In order to identify molecular markers and their downstream networks that can potentially be targeted for TNB
Publikováno v:
Cancer Research. 79:P5-11
Background: CDK4/6 inhibition combined with endocrine therapy is now a standard of care for advanced estrogen receptor (ER) positive breast cancer. Predictive genetic landscape and mechanisms of resistance to CDK4/6 inhibitors have not been described
Autor:
Carmen Maria Barnes, Ellen Filvaroff, Shi Tao, Mehnaz Malek, Gordon L. Bray, Winfried Elis, Yumin Dai, Konstantinos Mavrommatis, Lixin Qiao, Terri Jones, Ida Aronchik, Beebe Lisa, Matt Labenski
Publikováno v:
Molecular Cancer Research. 17:642-654
As a critical signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven by activation of the MAPK pathway. Utility of targeting the MAPK pathway has been demonstrated by clinical responses to inhibitors of MEK1/2 or RAF kinase
Autor:
Junji Tsurutani, Iori Taki-Takemoto, Kaori Nakatani, Motoi Ohba, Tohru Ohmori, Toshimitsu Yamaoka, Ken-Ichi Fujita, Daisuke Kamei, Satoru Arata, Shinichi Iwai, Sojiro Kusumoto
Publikováno v:
Molecular Cancer Therapeutics. 18:112-126
The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs